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SUMMARY
Mdmx is a critical negative regulator of the p53 pathway that is stoichiometrically limiting in some tissues.
Posttranslational modification and degradation of Mdmx after DNA damage have been proposed to be
essential for p53 activation. We tested this model in vivo, where critical stoichiometric relationships are
preserved. We generated an Mdmx mutant mouse in which three conserved serines (S341, S367, S402)
targeted by DNA-damage-activated kinases were replaced by alanines to investigate whether modifications
of these residues are important for Mdmx degradation and p53 activation. The mutant mice were remarkably
resistant to radiation, and very susceptible to Myc-induced lymphomagenesis. These data demonstrate that
Mdmx downregulation is crucial for effective p53-mediated radiation responses and tumor suppression
in vivo.INTRODUCTION
The p53 tumor suppressor is a transcription factor that is acti-
vated by diverse conditions to induce or repress hundreds of
protein- and miRNA-encoding genes (Toledo and Wahl, 2006).
Its activation elicits responses ranging from reversible cell-cycle
arrest to cellular senescence, cell death, blastocyst implantation,
or cytokine induction to recruit the immune system (Riley et al.,
2008). Its critical role in tumor suppression is evident from the
tumor predisposition of mice and humans harboring germline
p53 mutations (reviewed by Varley, 2003), and its mutation and
loss of heterozygosity in 50% of human cancers (Vousden and
Lu, 2002).
p53 function is also compromised in tumors encoding wild-
type p53. This typically occurs by overexpression of either one
of its two negative regulators, the oncoproteins Mdm2 and
Mdmx (Marine and Jochemsen, 2005), or by loss of the tumor
suppressor Arf (Eischen et al., 1999), which antagonizes Mdm2
(see below). Mice lacking either Mdm2 or Mdmx die during
embryogenesis, and the embryonic lethality is rescued by p53deletion (Jones et al., 1995; Montes de Oca Luna et al., 1995; Par-
ant et al., 2001; Migliorini et al., 2002). This demonstrates that
Mdm2 and Mdmx serve nonredundant functions in p53 regula-
tion. Both proteins bind to the same region in the p53 transcrip-
tion activation domain, and inhibit p53-dependent transcription
(reviewed by Marine et al., 2007). In addition, Mdm2 functions
as a RING domain E3 ubiquitin ligase to mediate p53 degradation
(Fang et al., 2000; Michael and Oren, 2003). Whereas Mdmx is
also a RING domain protein that is highly homologous to
Mdm2, it does not exhibit detectable E3 ligase activity (Stad
et al., 2001). However, several studies have indicated that
Mdmx can heterodimerize with Mdm2 and enhance or even
rescue Mdm2 ligase activity (Uldrijan et al., 2007; Poyurovsky
et al., 2007; Singh et al., 2007; Kawai et al., 2007). As with other
RING domain E3 ligases such as BRCA1 and BARD1 (Christen-
sen et al., 2007), it is likely that an Mdmx/Mdm2 heterodimer
forms a more optimal interface to recruit one or more E2 ubiquitin
transferases required to ubiquitylate p53 (Linke et al., 2008).
It has long been known that DNA double-strand breaks acti-
vate the ATM and Chk2 protein kinases to induce multipleSIGNIFICANCE
p53 function is sensitive to the levels of its negative regulators, Mdm2 and Mdmx. Cell-culture studies have suggested the
importance of posttranslational modifications in Mdm2 andMdmx for p53 activation, but this has not been rigorously tested
in vivo. This work shows that DNA damage and activated c-Myc both require phosphorylation of Mdmx in residues targeted
by the damage kinases ATM and Chk2 for robust p53 activation. Preventing Mdmx posttranslational modification stabilizes
this negative regulator, which mitigates p53 activation, and presumably enables c-Myc to drive tumor cells with defective
genomes into cycle in vivo. The data also stress the relevance of Mdmx as a potential therapeutic target.
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1997; Prives, 1998; Maya et al., 2001). In vitro data suggest
that the N-terminal modifications of p53 near the Mdm2/Mdmx
binding site may serve to reduce p53 interaction with these
negative regulators, as well as enhancing association with the
histone acetyltransferase coactivators that bind to the same
region (Grossman et al., 1998). In mice, p53 posttranslational
modifications serve the important function of fine-tuning p53
activity in different tissues (reviewed by Toledo and Wahl, 2006).
Another important contribution to p53 activation is the DNA-
damage-induced, accelerated degradation of Mdm2 and
Mdmx, which limits their ability to antagonize p53. We previously
showed that phosphorylation of Mdm2 by DNA-damage-
induced kinases accelerates Mdm2 autodegradation (Stommel
and Wahl, 2004). Similarly, double-strand DNA breaks result in
phosphorylation of human Mdmx at Ser342 and Ser367 by
Chk2 (Okamoto et al., 2005; Chen et al., 2005; LeBron et al.,
2006; Pereg et al., 2006) and Ser403 by ATM (Pereg et al.,
2005), all of which are needed for efficient Mdmx degradation.
These phosphorylations reduce binding of HAUSP, a ubiquitin-
specific protease (Meulmeester et al., 2005), which appears to
render Mdmx vulnerable to Mdm2-mediated ubiquitylation and
proteasomal degradation (Kawai et al., 2003; de Graaf et al.,
2003; Pan and Chen, 2003). Phosphorylations at Ser342 and
Ser367 of Mdmx are also necessary for interaction with 14-3-3
proteins, which affect Mdmx nuclear accumulation and degrada-
tion (Okamoto et al., 2005; LeBron et al., 2006; Pereg et al., 2006;
Jin et al., 2006), perhaps by serving as a steric barrier to limit
HAUSP binding.
The molecular intermediates that transduce signals from
activated oncogenes are beginning to be understood. As one
example, c-Myc is a transcription factor that activates numerous
genes including those involved in cell-cycle entry and progres-
sion, DNA replication, and metabolism (reviewed by Eilers and
Eisenman, 2008). Although it is clear that c-Myc overexpression
robustly activates p53, whether DNA damage is involved
remains controversial (e.g., see Vafa et al., 2002; Maclean
et al., 2003; Wade and Wahl, 2006). c-Myc overexpression
results in induction of the INK4a/Arf tumor suppressor (Zindy
et al., 1998). Arf binds to and inhibits Mdm2, which, as a conse-
quence, leads to p53 activation and induction of p53-mediated
downstream responses (Kamijo et al., 1998). The importance
of the Arf-Mdm2-p53 pathway in Myc-induced tumorigenesis
is evident in the Em-Myc lymphoma model where multiple copies
of the c-Myc gene are overexpressed in the B cell lineage
(Adams et al., 1985). Recently, an alternative mouse model
(iMycEm) was generated by inserting a single c-Myc gene into
the immunoglobulin heavy-chain enhancer (Em) (Park et al.,
2005). This mimics the human t(8;14)(q24;q32) translocation
that results in activation of c-Myc in human endemic Burkitt’s
lymphomas (Alitalo et al., 1987), and makes iMycEm a better
model for this disease. In both models, lymphomagenesis prog-
resses when p53 function is abrogated by loss ofArf, overexpres-
sion ofMdm2, or mutation of p53 (Eischen et al., 1999; Park et al.,
2005). Consistent with these observations, deleting either thep53
or Arf gene in Em-Myc mice accelerates the onset of lymphomas
to the same extent (Eischen et al., 1999; Schmitt et al., 1999;
Martins et al., 2006). In contrast, losing one copy of Mdm2
increases lymphoma latency (Eischen et al., 2004; Terzian et al.,34 Cancer Cell 16, 33–43, July 7, 2009 ª2009 Elsevier Inc.2007), whereas overexpressingMdm2 inEm-Mycmice decreases
tumor latency (Wang et al., 2008). Recently, Terzian et al. (2007)
showed that Em-Myc;Mdmx+/ mice also exhibited delayed
lymphomagenesis, suggesting a role for Mdmx in Myc-induced
tumorigenesis. However, the mechanism by which Mdmx
contributes to Myc-induced tumorigenesis remains unclear.
Understanding the factors that control p53 activation requires
that they be analyzed in physiologically relevant settings given
the exquisite sensitivity of p53 to the levels of its negative regu-
lators. We report the analysis of an Mdmx mutant mouse (here-
after Mdmx3SA) designed to test the importance of three highly
conserved serine residues targeted by the DNA-damage-acti-
vated kinases ATM (Ser402) and Chk2 (Ser341, Ser367) with
regard to irradiation and c-Myc-driven tumorigenicity.
RESULTS
Generation of Mdmx3SA Mice
We generated a mouse model in which the two highly conserved
Chk2 sites at serines 341 and 367 and the ATM site at Ser402 of
Mdmx were mutated to alanines to begin to evaluate the impor-
tance of Mdmx stability regulation in different tissues in vivo. The
targeting construct (Figure 1A) was electroporated into the
Mdmx locus of PrmCre embryonic stem cells, allowing for direct
transfer of the edited allele upon mating of transmitting males
(O’Gorman et al., 1997). Allele-specific PCR (see Figure S1 avail-
able online) and Southern blotting (Figure 1B) demonstrated that
5%–10% of all G418-resistant clones had undergone homolo-
gous recombination. Four independent homologous recombi-
nant ES clones were injected into C57BL/6 blastocysts to
produce Mdmx3SA chimeras, and 80% (4/5) of male chimeras
transmitted the mutant allele through the germline. Mdmx3SA
homozygotes were obtained by intercrossing heterozygous
mutant mice and were generated at Mendelian ratios typical
for the transmission of an autosomal allele lacking adverse
developmental effects (Figure 1C). Mdmx transcripts expressed
in thymus isolated from Mdmx3SA mice were sequenced, and
found to be wild-type for all codons except the three encoding
the targeted mutations (Figures 1D and 1E). The genetic back-
ground for all studies is 50% 129/Sv and 50% C57BL/6. We
have followed Mdmx3SA homozygotes for more than 18 months,
and have observed no obvious tumor predisposition or differ-
ences in vitality compared to WT mice (data not shown).
Mouse embryonic fibroblasts (MEFs) were isolated from
embryonic day 13.5 (E13.5) to determine the biochemical con-
sequences of DNA damage on cells expressing MdmxWT or
Mdmx3SA. Using an antibody specifically recognizing phospho-
S367 of Mdmx, we detected robust accumulation of a doublet
band inMdmxWT MEFs when cells were treated with the radiomi-
metic agent neocarzinostatin (NCS) plus proteasome inhibitors
(PI) (Figure 2A). Note that a weak signal of phospho-S367 was de-
tected in MdmxWT cells in the absence of exogenous damage
(Figure 2A, lane 1), indicating that an intrinsic stress occurring
during cell culture activates kinases that target this phosphoryla-
tion site in Mdmx. The slower-migrating band likely derives from
the phosphorylation at S402 (Pereg et al., 2005), because an anti-
phospho-S402 antibody only recognizes the slower-migrating
band in NCS- plus PI-treated MdmxWT MEFs (Figure 2B). Impor-
tantly, the single Mdmx band observed inMdmx3SA MEFs did not
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and 2B), which confirms the sequencing results (Figure 1D),
and further shows that one or more of the three mutated serines
engender the damage-induced mobility shift of the endogenous
gene product.
Mdmx3SA Mutations Impair DNA-Damage-Induced
Mdmx Degradation and p53 Stabilization
Previous studies in human cell lines suggest that Mdmx is
a stable protein in cells not exposed to exogenous challenges.
Upon DNA damage, Mdmx is modified by kinases and degraded
at the proteasome (Okamoto et al., 2005; Pereg et al., 2005,
2006; Chen et al., 2005; LeBron et al., 2006). Consistent with
previous studies, induction of DNA damage reduced the abun-
dance of MdmxWT in MEFs (Figures 2C and 2D), which can be
prevented by incubating cells with proteasome inhibitors (Fig-
ure S2). This indicates accelerated MdmxWT degradation follo-
wing DNA damage. By contrast, the 3SA mutations significantly
reduced DNA-damage-induced Mdmx degradation (Figures 2C
Figure 1. Generation ofMdmx3SA Allele and
Genotype Analysis of Mdmx3SA
(A) Schematic representation of the 30 end of the
mouse Mdmx locus, targeting vector, and homol-
ogous recombined Mdmx3SA allele, followed by
excision of loxP-flanked Neo cassette. The target-
ing construct contains a DTA negative selection
marker, 50 homology region with exon 10, and
a loxP-flanked Neo positive selection cassette,
followed by exon 11 with Mdmx mutations indi-
cated by stars and the 30 homology region. The
insertion of Neo introduces an additional AvrII
site that was used for Southern analysis with the
indicated external 50 and 30 probes. Cre expres-
sion in the male germline subsequently allows
excision of Neo.
(B) Southern blot analysis of targeted ES clones.
The 14 kb band represents the AvrII fragments
from the wild-type allele using both 50 and 30
probes. The recombined allele generates a 9 kb
fragment detected by the 50 probe and a 7 kb frag-
ment detected by the 30 probe.
(C) The expected and observed Mendelian ratios
from Mdmx3SA heterozygote breeding.
(D) Sequences ofMdmx transcript expressed from
MdmxWT and Mdmx3SA thymus. Yellow highlight
shows that the codons that encode S341, S367,
and S402 of the wild-type Mdmx are mutated in
the Mdmx3SA allele.
(E) PCR genotype of the Mdmx3SA mutant. PCR
amplifies the region surrounding the mutations to
produce a 579 bp fragment. The introduction of
mutations generates an NlaIV site that results in
366 and 213 bp fragments when PCR product is
digested with NlaIV.
and 2D). No further accumulation of
Mdmx3SA in the presence of proteasome
inhibitors was observed (Figure S2), indi-
cating that Mdmx3SA was quite resistant
to DNA-damage-induced degradation.
The mutations stabilize Mdmx in other
cell types as well, as Mdmx3SA in thymocytes was significantly
more resistant to damage-induced degradation than MdmxWT
after irradiation (Figure 2E). We also noticed that Mdmx3SA is
slightly more abundant than MdmxWT in the cells that were not
exposed to exogenous DNA damage. Concomitant with a more
stable Mdmx3SA after DNA damage, we observed lower accumu-
lation of p53 in Mdmx3SA cells, consistent with a model in which
Mdmx phosphorylation at these residues decreases its stability
while increasing p53 stability (Pereg et al., 2005; Figure S2).
The Effect of Mdmx Phosphorylations
on Protein Interactions
We next determined whether mutations of endogenous S341,
S367, and S402 would affect 14-3-3 binding after DNA damage,
as this has been suggested to contribute to Mdmx stability
control (Okamoto et al., 2005; Pereg et al., 2006; LeBron et al.,
2006). Cell lysates from MdmxWT, Mdmx3SA, and p53/;
Mdmx/ (2KO) MEFs were incubated with GST-14-3-3 re-
combinant proteins; glutathione beads were then used to isolateCancer Cell 16, 33–43, July 7, 2009 ª2009 Elsevier Inc. 35
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MdmxWT bound to 14-3-3 when cells were treated with NCS. In
the absence of NCS, a small portion of MdmxWT was also pulled
down by GST-14-3-3 (Figure 3A, lane 3, compare Mdmx to total
Mdmx), which is consistent with the observation in Figure 2A that
Mdmx is phosphorylated at low levels under our cell-culture
conditions. On the other hand, no interaction was detected with
Mdmx3SA. Subcellular fractionation analyses indicated that
Mdmx was predominantly cytoplasmic in untreated MdmxWT
and Mdmx3SA MEFs (Figure S3). Notably, the abundance of
nuclear Mdmx3SA was not affected by DNA damage (Figure S3).
We next investigated whether S341, S367, and S402 phos-
phorylations affect binding to Mdm2, as Mdmx degradation
upon DNA damage is mediated by Mdm2 (Kawai et al., 2003).
MdmxWT and Mdmx3SA MEFs were left untreated, or exposed
to NCS in the presence of proteasome inhibitors to maintain suffi-
cient Mdmx to enable detection, and then immunoprecipitated
with Mdmx-specific antibodies (Figure 3B). The data demon-
strate that similar amounts of Mdm2 were coimmunoprecipitated
with MdmxWT and Mdmx3SA following DNA damage. Mdm2 was
also coimmunoprecipitated with Mdmx3SA following treatment
with the topoisomerase I inhibitor etoposide (Figure S4). These
data lead us to conclude that DNA-damage-induced modifica-
tions on Mdmx have little effect on its interaction with Mdm2
when both proteins are expressed at endogenous levels.
p53 Activity Is Reduced in Mdmx3SA MEFs
and Thymocytes
Mdmx antagonizes p53-induced transcription by binding the
p53 transactivation domain (reviewed by Marine and Jochem-
sen, 2005; Toledo and Wahl, 2006). Because Mdmx degradation
Figure 2. Mdmx3SA Mutations Impair DNA-Damage-Induced Mdmx
Degradation
(A) MdmxWT and Mdmx3SA MEFs were preincubated with MG132 (10 mM) for
30 min, followed by 2 hr of NCS (200 ng/ml) incubation. Lysates were immuno-
precipitated with anti-Mdmx antibody, and blotted with anti-phospho-S367
antibody.
(B) MEFs were treated as described in (A). Lysates were immunoprecipitated
with anti-phospho-S402 Mdmx antibody, and blotted with anti-Mdmx antibody.
(C) MEFs were irradiated with 5 Gy of g-irradiation. Four hours later, cells were
lysed for western analysis.
(D) MEFs were treated with 200 ng/ml of NCS for 0, 2, and 6 hr. Lysates were
analyzed by western blotting using antibodies against Mdm2, Mdmx, and phos-
pho-S15 of p53.
(E) Thymocytes were irradiated with 5 Gy of g-irradiation. Four hours later, cells
were lysed for western analysis.36 Cancer Cell 16, 33–43, July 7, 2009 ª2009 Elsevier Inc.tracks with p53 activation (Wang et al., 2007), and Mdmx3SA is
more stable than MdmxWT after DNA damage, we predicted
that Mdmx3SA would compromise p53 activation. We therefore
compared the expression of the p53 target genes p21 and
puma in MEFs and thymocytes. Under normal cell-culture condi-
tions, p53 abundance in MdmxWT and Mdmx3SA cells was not
significantly different (Figure S9). However, we did observe
a lower basal level of p21 transcription in the Mdmx3SA-express-
ing cells (Figure 4A). Upon DNA damage, the fold induction of
p21 was slightly lower than that in MdmxWT cells (Figure S5),
but the absolute level of induced p21 transcript was 50% of the
wild-type level (Figure 4A). The reduced transcription of p21 was
manifested functionally by a reduced efficiency of DNA-damage-
induced arrest in MEFs (Figures 4B and 4C).
Induction of apoptosis is a second critical function of p53, and
induction of the proapoptotic gene puma is required for damage-
induced thymic apoptosis (Erlacher et al., 2005). Consistently, we
observed a lower basal level of puma transcription in Mdmx3SA
thymocytes and a slightly lower fold induction of puma after
exposing mice to 5 Gy of whole-body irradiation (Figures 4A
and S5). Importantly, we observed a significantly reduced abun-
dance of puma transcripts in Mdmx3SA thymocytes, and this
correlated with a significant decrease in the number of Mdmx3SA
apoptotic thymocytes after ionizing radiation (Figures 4D–4F).
To summarize, although the fold activation of p53-dependent
Figure 3. Analyses of Protein Interactions with Mdmx3SA in Re-
sponse to DNA Damage
(A) Cell lysates from MdmxWT, Mdmx3SA, and 2KO (p53/;Mdmx/) MEFs
either left untreated or treated with NCS (200 ng/ml) in the presence of
MG132 (10 mM) for 2 hr were incubated with glutathione beads prebound
with GST-14-3-33 proteins. Bead-bound proteins were eluted and analyzed
by western blotting.
(B) MEFs were either left untreated or treated with MG132 (10 mM) or treated
with MG132 plus NCS (200 ng/ml) and lysed 2 hr after. Cell lysates were immu-
noprecipitated with anti-Mdmx antibody, and blotted with anti-Mdm2, anti-
Mdmx, and anti-p53 antibodies. Anti-phospho-S15 of p53 antibody was
used as a control for detecting the DNA damage signal induced by NCS.
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(A) MEFs were treated with 500 ng/ml of NCS or 5-week-old mice were exposed to 5 Gy of g-irradiation. Six hours after NCS incubation or 4 hr after irradiation,
cells or thymus removed from MdmxWT (WT) and Mdmx3SA (3SA) mice were lysed for RNA isolation. p21 and puma gene expression was analyzed by real-time
quantitative PCR. Results were normalized to hprt mRNA. Error bars represent ±SD from three independent experiments.
(B and C) Cell-cycle arrest analysis. MEFs were either left untreated or exposed to 5 or 10 Gy of g-irradiation. Twenty-three hours after irradiation, 10 mM BrdU was
added in the cell culture for 1 hr before FACS analysis (B). BrdU-positive cells that represent cells in S phase during BrdU incorporation are quantified in (C). Error
bars represent ±SD from three independent experiments.
(D and E) Analysis of apoptosis in vivo. Mice were either left untreated or were exposed to 5 Gy of g-irradiation. Four hours later, thymocytes were isolated from
mice and stained with Annexin V-FITC for FACS analysis (D). Annexin V-positive cells that represent apoptotic cells are quantified in (E). Error bars represent ±SD
from three independent experiments.
(F) Apoptosis in splenocytes and thymocytes. Mice were treated as described in (D). Splenocytes and thymocytes were isolated and analyzed for the expression
of the active form of caspase-3 by western blotting with high (hi) or low exposure (lo).transactivation is similar in MdmxWT and Mdmx3SA tissues (Fig-
ure S5), the absolute mRNA level following stress is much lower
inMdmx3SA-expressing cells. We suggest that this absolute level
(rather than the fold change compared to basal expression) is
what ultimately dictates the biological response.Mdmx3SA Mice Show Increased Resistance to Death
Induced by Ionizing Radiation
Irradiation of mice at 10 Gy induces a p53-dependent hematopoi-
etic syndrome characterized by severe bone marrow depletion,
which results in death within 2 weeks of exposure (KomarovaCancer Cell 16, 33–43, July 7, 2009 ª2009 Elsevier Inc. 37
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stability affect the p53 pathway and its impact on radiosensitivity
in the hematopoietic compartment by comparing the effect of
10 Gy irradiation in MdmxWT and Mdmx3SA mice.
As expected, a single dose of 10 Gy whole-body ionizing irra-
diation in MdmxWT 129/Sv/C57BL/6 mice resulted in death of all
animals within 18 days (Figure 5A). Surprisingly, 60% of the irra-
diated Mdmx3SA homozygous mice lived at least 100 days post-
irradiation (Figure 5A). We performed complete pathological
analysis on a subset of MdmxWT and Mdmx3SA mice 13 days
postirradiation at the time when the first death was observed in
MdmxWT mice. Complete blood count revealed severe leucope-
nia, anemia, and thrombocytopenia in MdmxWT mice 13 days
postirradiation, whereasMdmx3SA mice exhibited only moderate
leucopenia and thrombocytopenia and mild anemia (Figure 5C).
Histopathological analysis did not show lesions in any other
tissues, including the gastrointestinal tract, in either MdmxWT
or Mdmx3SA mice (Figure 5B). This suggests that Mdmx3SA
mitigates p53 activity and confers radiation resistance predom-
inantly by affecting the hematopoietic compartment in vivo.
Consistent with these data, the majority of Mdmx3SA mice
show long-term survival following irradiation at a dose that is
lethal to WT animals. A subset of these mice exhibited moderate
anemia, leucopenia, and thrombocytopenia, which allowed
them to survive the acute mortality phase, but died of anemia
20–60 days postirradiation (data not shown).
Acceleration of c-Myc-Induced Lymphomagenesis
in Mdmx3SAMice
Loss of one Mdmx allele enhances p53-dependent apoptosis
and significantly delays the onset of c-Myc-induced lymphoma
(Terzian et al., 2007). However, whether modification of Mdmx
affects Myc-induced tumorigenesis is unclear. We have begun
to evaluate whether Mdmx phosphorylation modulates onco-
gene-induced tumorigenicity using the iMycEm lymphoma model.
These mice develop late-onset B cell lymphomas between 6 and
21 months of age which often exhibit changes in the Arf-Mdm2-
p53 tumor suppression pathway (Park et al., 2005). Mdmx3SA
Figure 5. Mdmx3SA Mice Are Resistant to a Lethal
Dose of Ionizing Irradiation
(A) Kaplan-Meier survival curves of 15 age-matched
MdmxWT (WT, n = 15) and Mdmx3SA homozygote (3SA,
n = 15) mice following exposure to 10 Gy of whole-body
g-irradiation.
(B) Histology of the gastrointestinal tract from MdmxWT
and Mdmx3SA mice showing no lesions associated with
irradiation (H&E). The scale bars represent 100 mm.
(C) Complete blood count analysis of white blood cells
(WBC), red blood cells (RBC), and platelets from MdmxWT
and Mdmx3SA mice, 13 days after 10 Gy of whole-body
g-irradiation. Error bars are ±SD from three animals.
mice were bred with heterozygous iMycEm mice
to generate iMycEm;+/+ and iMycEm;3SA/3SA
mice. Figure 6A shows that Mdmx3SA signifi-
cantly accelerated lymphomagenesis with 50%
survival at 3 months of age. Tumors arising from
iMycEm;3SA/3SA mice presented with severe
generalized lymphadenopathy and hepatosplenomegaly (Fig-
ure 6B). Histologically, most lymphomas were diffuse, B220+
IgM+IgD+ (data not shown), high-grade B cell lymphoma with
intermediate-sized cells, moderate to marked anisocytosis/ani-
sokaryosis, high mitotic index (8–16/high-power field), and abun-
dant apoptotic cells and large macrophages containing tingible
bodies producing a typical ‘‘starry-sky’’ effect (Figure 6C).
Tumors were highly infiltrative in several tissues including liver,
kidneys, lungs, meninges, eyes, and, occasionally, the gastroin-
testinal tract (Figure S6). Consistent with previous studies,
iMycEm;+/+ mice started to die by about 6 months of age with
50% survival about a year of age (Figure 6A; Park et al., 2005).
On gross examination, iMycEm;+/+ mice presented with marked
hepatosplenomegaly and variable lymphadenopathy. Histologi-
cally, lymphomas had similar features as those observed in the
iMycEm;3SA/3SA mice (data not shown).
We further investigated whether changes in Myc-induced
apoptosis or cell proliferation accompanied the early onset of
lymphomas in iMycEm;3SA/3SA mice. Using age-matched pretu-
mor littermates, we observed similar increases in apoptosis in
iMycEm;+/+ and iMycEm;3SA/3SA splenocytes when compared
to their littermates that did not contain iMycEm (Figure 6D).
However, we did detect significantly more iMycEm;3SA/3SA cells
in the S phase (Figure 6E). Additionally, we detected phosphor-
ylation of histone H2AX in the iMycEm;3SA/3SA splenocytes and
phosphorylation of Ser15 of p53 in iMycEm induced tumors,
consistent with an ongoing DNA damage response and acti-
vated ATM kinase pathway in these cells (Figure S7).
Tumors arising from overexpression of c-Myc require inactiva-
tion of the p53 pathway by either p53 mutation, loss of Arf, or
overexpression of Mdm2 (Eischen et al., 1999). We therefore
determined whether Mdmx3SA was sufficient to blunt the p53
response to c-Myc without additional disruption of the Arf-
Mdm2-p53 pathway. We observed increased levels of p53 and
Arf in tumors arising from iMycEm;+/+ and in one iMycEm;3SA/+
mouse (Figure 6F). This is consistent with the presence of one
or more mutant p53 alleles, as p53 negatively regulates Arf (Stott
et al., 1998). Indeed, one out of three iMycEm;+/+ tumors and one38 Cancer Cell 16, 33–43, July 7, 2009 ª2009 Elsevier Inc.
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(A) Kaplan-Meier survival curves of iMycEm;+/+ (n = 14) and iMycEm;3SA/3SA (n = 18) mice.
(B) Early-onset lymphoma in a 113-day-old iMycEm;3SA/3SA mouse. Dissection reveals severe enlargement of the spleen, liver, and most lymph nodes (notably
the mesenteric, cervical, brachial, axillary, mediastinal, pancreatic, renal, inguinal, and lumbar nodes).
(C) High-grade B cell lymphoma in iMycEm;3SA/3SA mice. Upper panel: the lymph node architecture is replaced with solid sheets of intermediate-size lympho-
cytes admixed with apoptotic tumor cells and large macrophages containing tingible bodies producing a typical ‘‘starry-sky’’ effect (H&E). The scale bar
represents 50 mm. Lower panel: intermediate-size lymphocytes with moderate to marked anisocytosis/anisokaryosis, high mitotic index, abnormal mitosis,
and apoptotic tumor cells (H&E). The scale bar represents 20 mm.
(D) Apoptosis analysis. Splenocytes were isolated from 8-week-old littermate mice of the indicated genotypes and stained with Annexin V-FITC for FACS
analysis. Annexin V-positive (i.e., apoptotic) cells were quantified. Error bars represent ±SD from three animals.
(E) Cell-cycle analysis. Eight-week-old littermate mice that contain different genotypes as indicated were intraperitoneally injected with 100 mg/kg of BrdU. Five
hours later, splenocytes were isolated and stained with anti-BrdU antibody for FACS analysis. BrdU-positive cells that represent cells in S phase were quantified.
Error bars represent ±SD from three animals.
(F) Levels of Mdm2, Mdmx, p53, and Arf assessed by immunoblotting in tumor extracts from iMycEm;+/+, iMycEm;3SA/+, and iMycEm;3SA/3SA mice. p53/;
Mdm2/ MEFs (2KO) and thymus irradiated in vivo (IR-thymus) were used as controls. The bottom panel shows the p53 status in those tumors (w, wild-type
p53; m, mutated p53). Tumor 1 from iMycEm;+/+ and tumor 2 from iMycEm;3SA/+ highlighted in red contain p53 mutations at R172H (CGC / CAC) and
K129T (AAG/ ACG), respectively (see Figure S8 for details).out of four iMycEm;3SA/+ tumors that were analyzed contained
p53 mutations at R172H and K129T, respectively (Figure S8).
By contrast, no p53 mutations were detected in ten iMycEm;
3SA/3SA tumors that were analyzed (data not shown).
DISCUSSION
Mdmx Turnover Is a Critical Component for p53
Activation In Vivo
The Mdmx3SA mouse model presented here establishes post-
translational modification of Mdmx as an important component
of the damage- and oncogene-responsive mechanisms that
activate p53 (Figure 7). Reducing Mdmx degradation compro-
mised p53 transactivation of its target genes and induction of
cell-cycle arrest and apoptosis. The Mdmx3SA mice exhibit
significantly reduced sensitivity of hematopoietic cells to radia-
tion, which renders Mdmx3SA mice extraordinarily resistant to
10 Gy of ionizing radiation (a myeloablative, lethal dose for
wild-type mice). Conversely, Mdmx3SA mice expressing the
iMycEm oncogene die rapidly of widely disseminated lymphoma(see below). Thus, Mdmx regulation is involved in cellular
responses to both DNA damage and some oncogenic stimuli.
Our data show that Mdmx3SA is slightly more abundant than
MdmxWT before DNA damage, suggesting the mutations render
Mdmx more stable during homeostatic growth. We infer that
a low level of stress during cell-culture conditions is responsible
for this effect. This is supported by the detection of phospho-
S367 in the absence of exogenous DNA damage (Figure 2A,
lane 1). This ‘‘constitutive’’ Mdmx phosphorylation is likely
responsible for degradation of MdmxWT, and thus contributes
to the increase in basal levels of Mdmx3SA. This may lead to
the lower basal p53 activity in Mdmx3SA, because Mdmx3SA is
now refractory to intrinsic damage-induced modification/degra-
dation and can limit p53-dependent transactivation. Neverthe-
less, the functional consequence of this difference in p53 basal
activity appears subtle for the following reasons: (1) Mdmx3SA
exhibits cell-cycle (Figure 4C) and apoptosis (Figure 4E) profiles
identical to MdmxWT in the absence of exogenous DNA damage,
and (2) there is no increased spontaneous tumor formation in
Mdmx3SA mice.Cancer Cell 16, 33–43, July 7, 2009 ª2009 Elsevier Inc. 39
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response to DNA damage was similar between MdmxWT and
Mdmx3SA cells, although the absolute level of p21 and puma
transcripts was lower in Mdmx3SA. The basal levels of p53 are
similar in Mdmx3SA and MdmxWT, but damage-induced p53
levels are consistently lower in Mdmx3SA (Figure S9). It is impor-
tant to note that the net activity of p53 results from a combination
of its abundance, the interaction with and stability of its negative
regulators, the effects of stress on other factors involved in p53
activation such as chromatin modifiers, etc. Note that, after
stress, Mdm2 level is typically lower in the mutant due to reduced
gene transcription. Thus, in Mdmx3SA cells after DNA damage,
there is generally less Mdm2 and more Mdmx than in MdmxWT
cells. This results in somewhat lower p53 accumulation. The
net of all these effects is the observed 2- to 3-fold decrease
in activity which is apparently sufficient to prevent the biological
responses required for extensive hematopoietic system
apoptosis or tumor suppression. These data emphasize the
importance of Mdmx regulation for setting basal and stress-
induced p53 activity, and the associated biological responses.
We previously showed that p53/Mdm2 or p53/Mdmx interac-
tions subsequent to DNA damage are readily detectable as long
as proteasome inhibitors are present (Stommel and Wahl, 2004;
Wang et al., 2007), implying that p53 posttranslational modifica-
tions alone are insufficient to prevent interactions with Mdm2/
Mdmx. We suggest that, in addition to p53 phosphorylation,
damage-induced posttranslational Mdm2/Mdmx modifications
are required to enable their accelerated degradation and
maximal activation of p53. Previous in vitro data showed that
when Mdmx is phosphorylated, HAUSP’s affinity for Mdmx is
reduced, and 14-3-3’s affinity is increased (Meulmeester et al.,
2005; Okamoto et al., 2005; Pereg et al., 2006; LeBron et al.,
2006). Consistent with this, data herein indicate that 14-3-3
binds only to phosphorylated Mdmx. Both basal and damage-
Figure 7. Mechanism for the Role of Mdmx Modification in the DNA
Damage and Oncogenic Signaling Pathway
Phosphorylations of Mdmx can be initiated either by DNA damage signaling or
by activated oncogenes. Phosphorylations of Mdmx modulate its interaction
with other proteins, such as 14-3-3, the protein analyzed in this study. Interac-
tion of Mdmx and 14-3-3 is required for accelerated Mdmx and Mdm2 degra-
dation after DNA damage, probably by limiting Mdm2/Mdmx interaction with
the deubiquitylase HAUSP (see text). Preferential degradation of Mdm2 and
Mdmx reduces their ability to interact with and antagonize p53 function,
leading to p53 activation. The 3SA mutations introduced in this study prevent
14-3-3 interaction after DNA damage, leading to Mdmx-Mdm2 stabilization
and a corresponding increased ability to degrade p53.40 Cancer Cell 16, 33–43, July 7, 2009 ª2009 Elsevier Inc.induced associations of Mdmx with 14-3-3 (Figure 3) were abol-
ished by the 3SA mutation. This indicates that cultured cells
experience sufficient stress to induce a damage response. Addi-
tionally, it may provide an explanation for the slightly elevated
basal levels of Mdmx3SA compared to MdmxWT cells, because
Mdmx3SA is refractory to the endogenous damage signaling
and can no longer bind 14-4-3. Loss of interaction between
Mdmx3SA and 14-3-3 leads us to speculate that competition
between 14-3-3 and HAUSP for Mdmx binding after DNA
damage contributes to Mdmx stability control. Furthermore, we
infer that 14-3-3 binding is not required for Mdmx nuclear locali-
zation per se, but that it can regulate the abundance of nuclear
Mdmx following DNA damage as indicated by previous studies
(LeBron et al., 2006; Pereg et al., 2006). Whether this is due to per-
turbed nuclear degradation of Mdmx or is a consequence of
altered nucleo-cytoplasmic shuttling remains to be determined.
Mdmx Regulation Contributes to Oncogene-Mediated
Activation of p53
Oncogene overexpression can activate p53 by several mecha-
nisms (reviewed by Halazonetis et al., 2008). As one example,
expressing c-Myc under the control of the Em immunoglobulin
enhancer induces Arf expression, which antagonizes Mdm2-
mediated p53 ubiquitylation, resulting in p53 activation (Zindy
et al., 1998). It has been suggested that Arf does not interact
with Mdmx directly (Wang et al., 2001; Li et al., 2002; Laurie
et al., 2006). However, Mdmx and Mdm2 form a heterodimer
and Mdmx haploinsufficiency clearly delays the onset of Myc-
induced lymphomas (Terzian et al., 2007), implicating the
involvement of Mdmx in the Arf-Mdm2-p53 tumor suppressor
pathway. Note that most of the tumors arising from both
Em-Myc mice and iMycEm mice exhibit loss of Arf, p53 mutation,
or Mdm2 overexpression (Eischen et al., 1999; Park et al., 2005).
By contrast, we found no evidence of these changes in tumors
arising from iMycEm;3SA/3SA mice. Although Mdm2 levels
appear slightly elevated in some tumors arising from iMycEm;
3SA/3SA mice compared to iMycEm;+/+ mice, this probably
reflects the lower expression of Mdm2 in WT tumors that have
suffered p53 mutations. Together, these data indicate that alter-
ations in Mdmx (either modification or stability) are sufficient to
mitigate p53 function in Myc-induced lymphomagenesis.
Tumors isolated from patients often exhibit markers of double-
stranded DNA damage, including phospho-ATM, phospho-
Chk2, and phospho-histone H2AX (Bartkova et al., 2005), sug-
gesting that ongoing DNA damage is a hallmark of many tumor
types. Our attempts to study Mdmx phosphorylation in Myc-
induced tumors by immunofluorescence were unsuccessful
due to the difficulty of preserving the unstable phosphorylated
form of Mdmx in vivo and current technical limitations of the
available antibodies (data not shown). However, we did detect
phospho-H2AX in iMycEm;3SA/3SA splenocytes, and phosphor-
ylation of S15p53 in iMycEm induced tumors, suggesting the
presence of double-strand breaks and an activated ATM kinase
pathway. Consistent with this inference, Myc-induced lympho-
magenesis is accelerated in ATM deficient mice (Maclean
et al., 2007). This provides a strong link between the DNA
damage response and Myc-induced lymphomas. Whether the
damage is triggered through Myc-induced replication stress or
occurs as a consequence of lymphomagenesis itself remains
Cancer Cell
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of the Akt kinase (Lopez-Pajares et al., 2008), and therefore we
cannot exclude the possibility that members of other kinase fami-
lies may also mediate the phosphorylations of Mdmx in response
toMycactivation. Interestingly, we observedsimilar levelsof Myc-
induced apoptosis in iMycEm;+/+ and iMycEm;3SA/3SA mice,
whereas increased proliferation of lymphocytes was detected in
iMycEm;3SA/3SA mice. Thus, Mdmx3SA may blunt the p53
response to activated Myc, allowing more cells to enter S phase.
This could explain why lymphomas develop with a shorter latency,
and appear more aggressive in the Mdmx3SA background.
Indeed, in the absence of iMycEm, no increased spontaneous
tumorigenesis was observed in Mdmx3SA mice. This indicates
that accelerated lymphomagenesis in iMycEm;3SA/3SA mice is
via mitigation of an oncogene-induced antiproliferative response,
rather than simple attenuation of basal p53 activity. In summary,
our data clearly implicate Mdmx phosphorylation(s) as a deter-
minant of oncogene-induced tumorigenesis.
Mdmx Modification in Tumorigenesis
and as a Therapeutic Target
Our findings indicate that Mdmx modification is another example
of the much-wielded ‘‘double-edged sword.’’ On the one hand,
phosphorylation of Mdmx appears to be critical for Mdmx degra-
dation and tumor suppression. Thus, the function of factors
controlling this process may be attenuated in cancer, and their
(re)activation may be beneficial for cancer therapy. Conversely,
damage-induced modification of Mdmx enhances p53-depen-
dent radiosensitivity. In this case, inhibition of Mdmx phosphor-
ylation may be a strategy to prevent cytotoxicity in normal
tissues exposed to environmental or chemotherapeutic geno-
toxins. A precedent for this approach is the use of the p53 inhib-
itor pifithrin-a as a radioprotective agent in vivo (Burdelya et al.,
2006). Although challenging, finding ways to promote selective
Mdmx degradation in tumor versus normal cells may increase
the efficacy of current p53-targeted therapies.
EXPERIMENTAL PROCEDURES
Targeting Construct
Fragments of mouse genomicMdmx gene, extending from intron 9 through the
30 UTR, were cloned into pACYC177 (New England Biolabs) using Red/ET
recombination (Gene Bridges). Mutations that substitute serines 341, 367,
and 402 with alanines were introduced by site-directed mutagenesis using
the QuikChange kit (Stratagene). A positive selection marker, the neomycin
(Neo) resistance gene, driven by the PGK promoter and flanked by loxP sites,
was introduced into an AvrII site upstream of exon 11. A negative selection
marker, diphtheria toxin A (DTA), driven by the PGK promoter, was inserted
into the targeting vector upstream of exon 10. The exons, the intron-exon
boundary, Neo, and DTA were sequenced to ensure no unexpected mutations
were introduced during the cloning.
Generating and Genotyping Mdmx3SA Mice
The targeting vector was linearized with NotI and electroporated into PrmCre
129/Sv ES cells before being selected for neomycin resistance. Homologous
recombination was confirmed by PCR screening and Southern blotting with
AvrII-digested genomic DNA. Southern probes were generated from PCR
amplification in the regions external to the targeting vector. Four independent
ES clones containing the targeted Mdmx3SA allele were injected into C57BL/6
blastocysts, which were then implanted into pseudopregnant females. Germ-
line transmission was confirmed by breeding chimeras with C57BL/6 mice.
The offspring were PCR genotyped using a primer set (3SA-fw: 50-AAT TTGTTC AGG TCT CAG GTT GG-30 and 3SA-rv: 50-CAT AAG CTA CAC GGC
TTC AAG AC-30), followed by NlaIV digestion. Heterozygous mutant mice
were interbred to produce homozygous mutant mice. All animals described
were on a mixed 129/Sv X C57BL/6 background.
Protein Analysis
Cells or tissues were lysed in RIPA buffer (50 mM Tris-HCl [pH 8], 150 mM
NaCl, 0.1% SDS, 0.5% Na deoxycholate, 1% NP40) or in Giordano buffer
(50 mM Tris-HCl [pH 7.4], 250 mM NaCl, 0.1% Triton X-100, 5 mM EDTA).
Protein extracts were analyzed either by direct western blotting or by immuno-
precipitation/western. Mdmx immunoprecipitations were performed with
a mixture of rabbit polyclonal antibodies, p55, and p56 (Ramos et al., 2001).
Blots were probed with antibodies specific for Mdm2 (4B2 [Calbiochem] and
2A10 [gift from G. Zambetti]), Mdmx (MX-82; Sigma), P-S367Mdmx and
P-S402Mdmx (both gifts from Y. Shiloh), p53 (1C12; Cell Signaling Technolo-
gies), P-S15p53 (Cell Signaling Technologies), Arf (Ab80; Abcam), active cas-
pase-3 (cleaved-caspase-3 Asp175; Cell Signaling Technologies), PARP
(Santa Cruz Biotechnology), tubulin (Sigma), and actin (Sigma).
Mdmx/14-3-3 Interaction
Protein extracts made in Giordano buffer were incubated for 2 hr with gluta-
thione beads to which bacterially produced GST-14-3-33was coupled. Subse-
quently, beads were washed four times with Giordano buffer, and bound
proteins were eluted with sample buffer and analyzed by western blotting.
Quantitative PCR
RNA was isolated and subjected to real-time quantitative PCR as described
previously (Krummel et al., 2005).
Flow Cytometry
For cell-cycle analysis, MEFs were irradiated with 5 or 10 Gy g-irradiation and
incubated for 23 hr, followed by 1 hr incubation with 10 mM BrdU (Sigma). For
cell proliferation analysis in the iMycEm study, mice were intraperitoneally in-
jected with 100 mg/ml of BrdU (Sigma). Five hours later, splenocytes were iso-
lated. Cells were then fixed in 70% ethanol and stained with FITC anti-BrdU
and propidium iodide. For the apoptosis assay, mice were exposed to 5 Gy
of whole-body irradiation. Four hours later, mice were sacrificed and thymo-
cytes or splenocytes were isolated and stained with Annexin-V-FITC (BD
Biosciences) for analysis. For both cell-cycle and apoptosis analysis, the cells
were sorted using a Becton Dickinson FACScan machine and data were
analyzed using CellQuest Pro.
Animal Studies
All procedures were approved by the Salk Institutional Animal Care and Use
Committee. For the irradiation study, age- and gender-matched mice were
exposed to whole-body irradiation with a [60Co]g-irradiator. For the tumorige-
nicity study, Mdmx3SA/+ mice were bred with iMycEm mice to generate
iMycEm;+/+, iMycEm;3SA/+, and iMycEm;3SA/3SAmice. Animals were observed
daily for signs of morbidity and tumor development. Tumor development was
monitored by palpation of the abdomen and cervical, axillary, and inguinal
regions. Mice were euthanized humanely when moribund or when reaching
tumor-specific endpoints. Portions of all tumors and major organs were fixed
in formalin for histopathology and snap frozen for protein and RNA extraction.
SUPPLEMENTAL DATA
Supplemental Data include nine figures and can be found with this article online
at http://www.cell.com/cancer-cell/supplemental/S1535-6108(09)00174-3.
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